EquityBulls

Latest News

Markets rally on Diplomatic Progress and Nvidia Beat
GRSE Launches Next-Gen OPV: Crafted for Vigilance, Built for Victory
Muthoot Finance Ranked India's No. 1 Most Trusted Financial Services Brand for 10th Consecutive Year
Ampere Magnus G Max by Greaves Electric Mobility Wins 'Family Scooter of the Year' at Times Drive Auto Summit and Awards 2026
Eris delivers 11% yoy growth in Domestic Formulations with 37% EBIDTA margin in FY26

Keywords Selected: Biosimilar

Stock Report

Lupin receives European Commission approval for Biosimilar Ranibizumab
Zydus launches biosimilar Aflibercept 2 mg ANYRA™ for advancing ophthalmic care
Biocon Biologics Secures Full Global Rights to Biosimilar Adalimumab through Expanded FKB In-Licensing Agreement
Lupin receives Positive CHMP Opinion for Biosimilar Ranibizumab
Biocon Biologics Signs Settlement and License Agreement to Commercialize Biosimilar Aflibercept Worldwide
Lupin and Valorum Enter into an Exclusive Licensing Agreement for Biosimilar Armlupeg™ in the United States
Lupin and Zentiva Sign License and Supply Agreement for Commercializing Certolizumab
Lupin Ltd enters into agreement with Zentiva for biosimilar Certolizumab Pegol
CuraTeQ Biologics receives positive opinion for biosimilar Dazublys® from EMA
Biocon Biologics secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S.
Biocon Biologics announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio
European Commission approves Biocon Biologics' Ustekinumab Biosimilar
U.S.FDA Approves Biocon Biologics' YESINTEK™, Bmab 1200 biosimilar to J&J's Stelara® (Ustekinumab)
Dr. Reddy's receives positive CHMP opinion from European Medicines Agency for its proposed Rituximab biosimilar
Zydus and Dr. Reddy's announce licensing agreement for co‐marketing of Pertuzumab biosimilar
EMA Approves Biocon Biologics' New mAbs Facility in India and Renews GMP Certifications for India and Malaysia Sites
Ipca Laboratories Ltd enters into technology transfer agreement with Omexa Formulary Pvt Ltd
CuraTeQ Biologics announces the successful Phase 1 clinical study outcome of their BP11 product
Biocon Biologics Secures Canada Market Entry Date for YESAFILI®, a Proposed Biosimilar to EYLEA®
CuraTeQ Biologics receives recommendation for grant of marketing authorization of 'biosimilar trastuzumab' from SEC operating under the aegis of CDSCO
Glenmark is the first to launch Biosimilar of Popular Anti‐Diabetic Drug, Liraglutide, in India
Biocon Biologics Receives European Commission Approval for YESAFILI®, Biosimilar Aflibercept
Biocon Biologics announces Positive CHMP Opinion for YESAFILI®, Biosimilar Aflibercept
CuraTeQ obtains exclusive rights for BioFactura's Ustekinumab biosimilar